Content about Leuprolide

October 28, 2011
FDA approves supplemental new drug application for Abbott's Lupron Depot-PED

The Food and Drug Administration has approved a supplemental new drug application related to a drug made by Abbott, the company said.

ABBOTT PARK, Ill. — The Food and Drug Administration has approved a supplemental new drug application related to a drug made by Abbott, the company said.

June 20, 2011
Abbott receives FDA approval for Lupron Depot

The Food and Drug Administration has approved a new formulation of an injectable drug made by Abbott for prostate cancer.

ABBOTT PARK, Ill. — The Food and Drug Administration has approved a new formulation of an injectable drug made by Abbott for prostate cancer.

Abbott announced Monday the approval of a 45-mg, six-month formulation of Lupron Depot (leuprolide acetate) for advanced prostate cancer. Previous formulations have allowed patients to receive the drug every month or every three or four months.

October 19, 2010
Cardiovascular, diabetes risk associated with prostate cancer drug class

Patients taking a certain class of drugs mostly used for prostate cancer may be at...

SILVER SPRING, Md. Patients taking a certain class of drugs mostly used for prostate cancer may be at higher risk of heart disease and diabetes, the Food and Drug Administration warned on Wednesday.

 

May 2, 2010
FDA: Certain prostate cancer drugs may cause other health problems

The Food and Drug Administration is investigating a possible link between drugs commonly used to...

March 11, 2010
Watson gets FDA approval for Trelstar

The Food and Drug Administration has approved a Watson Pharmaceuticals drug for treating cancer, Watson...